Find Toremifene Citrate manufacturers, exporters & distributors on PharmaCompass

Toremifene Citrate

Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

8 API Suppliers, 6 USDMF, 2 JDMF, 1 EU WC, 4 NDC API, 4 Listed Suppliers

8 API Suppliers
6 USDMF
2 JDMF
1 EU WC
4 NDC API
4 Listed Suppliers

FINISHED DOSAGE FORMULATIONS

10 FDF Dossiers, 3 FDA Orange Book, 4 Europe, 2 Australia, 1 South Africa

10 FDF Dossiers
3 FDA Orange Book
4 Europe
2 Australia
1 South Africa

RELATED EXCIPIENT COMPANIES

4 SPI Pharma, 1 DKSH, 3 Faran Shimi Pharmaceutical, 1 Boai NKY Pharmaceuticals Ltd, 11 Gangwal Healthcare, 6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 9 BASF, 4 DFE Pharma, 5 Gangwal Chemicals, 1 Ideal Cures Pvt Ltd, 3 Ingredion Pharma Solutions, 10 Kerry, 9 Microlex e.U, 1 Novo Excipients, 3 Pharmatrans-Sanaq, 3 Pluviaendo, 3 Prachin Chemical, 15 Roquette, 1 Seppic, 3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 9 Sigachi Industries, 1 Ulanqab Kema New Material, 3 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

46 Fillers, Diluents & Binders, 27 Direct Compression, 20 Disintegrants & Superdisintegrants, 14 Thickeners and Stabilizers, 13 Co-Processed Excipients, 13 Granulation, 12 Lubricants & Glidants, 8 Controlled & Modified Release, 7 Solubilizers, 5 Chewable & Orodispersible Aids, 5 Taste Masking, 4 Coating Systems & Additives, 3 Emulsifying Agents, 2 Parenteral, 2 Film Formers & Plasticizers, 1 Rheology Modifiers, 1 API Stability Enhancers

excipientsByApplications
46 Fillers, Diluents & Binders
27 Direct Compression
20 Disintegrants & Superdisintegrants
14 Thickeners and Stabilizers
13 Co-Processed Excipients
13 Granulation
12 Lubricants & Glidants
8 Controlled & Modified Release
7 Solubilizers
5 Chewable & Orodispersible Aids
5 Taste Masking
4 Coating Systems & Additives
3 Emulsifying Agents
2 Parenteral
2 Film Formers & Plasticizers
1 Rheology Modifiers
1 API Stability Enhancers

DIGITAL CONTENT

3 NEWS #PharmaBuzz

media
3 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions, 4 Finished Drug Prices, 1 Annual Reports

globalSalesInformation
2 US Medicaid Prescriptions
4 Finished Drug Prices
1 Annual Reports

PATENTS & EXCLUSIVITIES

1 Health Canada Patents

patents
1 Health Canada Patents

REF. STANDARDS & IMPURITIES

2 Others

otherSolutions
2 Others

ANALYTICAL

1 BioAnalytical Methods

otherMethods
1 BioAnalytical Methods

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

1,342,469

Annual Reports (USD Million)

Finished Drug Prices

109 RELATED EXCIPIENT COMPANIES

183EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 89778-27-8, Fareston, Toremifene citrate [usan], Toremifene (citrate), Fc 1157a, Nk 622

Molecular Formula

C₃₂H₃₆ClNO₈

Molecular Weight

598.1 g/mol

InChI Key

IWEQQRMGNVVKQW-OQKDUQJOSA-N

FDA UNII

2498Y783QT

A first generation selective estrogen receptor modulator (SERM). Like TAMOXIFEN, it is an estrogen agonist for bone tissue and cholesterol metabolism but is antagonistic on mammary and uterine tissue.

1 2D Structure

Toremifene Citrate

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid

2.1.2 InChI

InChI=1S/C26H28ClNO.C6H8O7/c1-28(2)19-20-29-24-15-13-23(14-16-24)26(22-11-7-4-8-12-22)25(17-18-27)21-9-5-3-6-10-21;7-3(8)1-6(13,5(11)12)2-4(9)10/h3-16H,17-20H2,1-2H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/b26-25-;

2.1.3 InChI Key

IWEQQRMGNVVKQW-OQKDUQJOSA-N

2.1.4 Canonical SMILES

CN(C)CCOC1=CC=C(C=C1)C(=C(CCCl)C2=CC=CC=C2)C3=CC=CC=C3.C(C(=O)O)C(CC(=O)O)(C(=O)O)O

2.1.5 Isomeric SMILES

CN(C)CCOC1=CC=C(C=C1)/C(=C(/CCCl)\C2=CC=CC=C2)/C3=CC=CC=C3.C(C(=O)O)C(CC(=O)O)(C(=O)O)O

2.2 Other Identifiers

2.2.1 UNII

2498Y783QT

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Citrate, Toremifene

2. Fareston

3. Fc 1157a

4. Fc-1157a

5. Fc1157a

6. Toremifene

7. Toremifene Citrate (1:1)

8. Toremifene, (e)-isomer

2.3.2 Depositor-Supplied Synonyms

1. 89778-27-8

2. Fareston

3. Toremifene Citrate [usan]

4. Toremifene (citrate)

5. Fc 1157a

6. Nk 622

7. Nsc 613680

8. Fc-1157a

9. 89778-27-8 (citrate)

10. Nsc-613680

11. Nsc613680

12. 2-(p-((z)-4-chloro-1,2-diphenyl-1-butenyl)phenoxy)-n,n-dimethylethylamine Citrate (1:1)

13. 2498y783qt

14. Toremifene Citrate (fareston, Acapodene)

15. Dsstox_cid_1367

16. Dsstox_rid_76113

17. Dsstox_gsid_21367

18. (z)-2-(4-(4-chloro-1,2-diphenylbut-1-en-1-yl)phenoxy)-n,n-dimethylethan-1-amine 2-hydroxypropane-1,2,3-tricarboxylate

19. Ethanamine, 2-(4-(4-chloro-1,2-diphenyl-1-butenyl)phenoxy)-n,n-dimethyl-, (z)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)

20. (2-{4-[(1z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenoxy}ethyl)dimethylamine; 2-hydroxypropane-1,2,3-tricarboxylic Acid

21. 2-({4-[(1z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenyl}oxy)-n,n-dimethylethanamine 2-hydroxypropane-1,2,3-tricarboxylate (salt)

22. Cas-89778-27-8

23. Ccris 6719

24. Unii-2498y783qt

25. 2-[p-[(z)-4-chloro-1,2-diphenyl-1-butenyl]phenoxy]-n,n-dimethylethylamine Citrate (1:1)

26. Cpd000469213

27. Schembl4564

28. (z)-4-chloro-1,2-diphenyl-1-(4-(2-(n,n-dimethylamino)ethoxy)phenyl)-1-butene Citrate (1:1)

29. Mls001306432

30. Mls006011608

31. Chebi:9636

32. Toremifene Citrate [mi]

33. Chembl1200675

34. Dtxsid2021367

35. Toremifene Citrate (jan/usan)

36. Toremifene Citrate [jan]

37. Hms2052c03

38. Hms2230p09

39. Hms3264l11

40. Pharmakon1600-01505682

41. Toremifene Citrate [vandf]

42. Toremifene Citrate [mart.]

43. Hy-b0005

44. Toremifene Citrate [who-dd]

45. Tox21_111877

46. Tox21_301740

47. Mfcd01729016

48. Nsc759190

49. S1776

50. Akos015888270

51. Ac-1985

52. Ccg-101072

53. Cs-1272

54. Ks-5242

55. Nc00322

56. Nsc-759190

57. 2-[4-[(z)-4-chloro-1,2-diphenyl-but-1-enyl]phenoxy]-n,n-dimethyl-ethanamine; Citric Acid

58. Toremifene Citrate [orange Book]

59. Ncgc00255310-01

60. 2-[4-[(z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]-n,n-dimethylethanamine; 2-hydroxypropane-1,2,3-tricarboxylic Acid

61. Smr004703372

62. Toremifene Citrate Salt, >=98% (hplc)

63. Sw197702-3

64. T2832

65. D00967

66. 778t267

67. A843307

68. Sr-01000763502-3

69. Q27253831

70. 2-[p-[(z)-4-chloro-1,n- Dimethylethylamine Citrate (1:1)

71. (z)-2-[4-(4-chloro-1,2-diphenyl-1-butenyl)phenoxy]-n,n-dimethylethanamine Citrate

72. (z)-2-[4-(4-chloro-1,n- Dimethylethanamine, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)

73. (z)-4-chloro-1-(4-dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene Citrate

74. (z)-2-(4-(4-chloro-1,2-diphenylbut-1-en-1-yl)phenoxy)-n,n-dimethylethanamine 2-hydroxypropane-1,2,3-tricarboxylate

75. (z)-2-(4-(4-chloro-1,2-diphenylbut-1-enyl)phenoxy)-n,n-dimethylethanamine 2-hydroxypropane-1,2,3-tricarboxylate

76. 2-[4-[(z)-4-chloranyl-1,2-diphenyl-but-1-enyl]phenoxy]-n,n-dimethyl-ethanamine; 2-oxidanylpropane-1,2,3-tricarboxylic Acid

2.4 Create Date

2005-03-26

3 Chemical and Physical Properties

Molecular Formula	C₃₂H₃₆ClNO₈
Molecular Weight	598.1 g/mol
Hydrogen Bond Donor Count	4
Hydrogen Bond Acceptor Count	9
Rotatable Bond Count	14
Exact Mass	597.2129448 g/mol
Monoisotopic Mass	597.2129448 g/mol
Topological Polar Surface Area	145 Å²
Heavy Atom Count	42
Formal Charge	0
Complexity	710
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	1
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	2

4 Drug and Medication Information

4.1 Drug Indication

First line hormone treatment of hormone-dependent metastatic breast cancer in postmenopausal patients.

Fareston is not recommended for patients with estrogen receptor negative tumours.

5 Pharmacology and Biochemistry

5.1 MeSH Pharmacological Classification

Antineoplastic Agents, Hormonal

Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079) (See all compounds classified as Antineoplastic Agents, Hormonal.)

Bone Density Conservation Agents

Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS. (See all compounds classified as Bone Density Conservation Agents.)

Selective Estrogen Receptor Modulators

A structurally diverse group of compounds distinguished from ESTROGENS by their ability to bind and activate ESTROGEN RECEPTORS but act as either an agonist or antagonist depending on the tissue type and hormonal milieu. They are classified as either first generation because they demonstrate estrogen agonist properties in the ENDOMETRIUM or second generation based on their patterns of tissue specificity. (Horm Res 1997;48:155-63) (See all compounds classified as Selective Estrogen Receptor Modulators.)

5.2 FDA Pharmacological Classification

5.2.1 Pharmacological Classes

Selective Estrogen Receptor Modulators [MoA]; Estrogen Agonist/Antagonist [EPC]

5.3 ATC Code

L02BA02

API SUPPLIERS